Barclays Reiterates “€65.00” Price Target for Sanofi (SAN)

Sanofi (EPA:SAN) received a €65.00 ($77.38) target price from stock analysts at Barclays in a research note issued to investors on Tuesday. The brokerage currently has a “sell” rating on the stock. Barclays’ target price indicates a potential downside of 8.62% from the stock’s previous close.

A number of other brokerages have also recently weighed in on SAN. Jefferies Group set a €80.00 ($95.24) price objective on shares of Sanofi and gave the stock a “neutral” rating in a report on Tuesday, January 16th. Deutsche Bank set a €93.00 ($110.71) price objective on shares of Sanofi and gave the stock a “buy” rating in a report on Friday. Berenberg Bank set a €97.00 ($115.48) price objective on shares of Sanofi and gave the stock a “neutral” rating in a report on Monday. S&P Global set a €83.00 ($98.81) price objective on shares of Sanofi and gave the stock a “neutral” rating in a report on Friday, November 3rd. Finally, Goldman Sachs Group set a €82.00 ($97.62) price objective on shares of Sanofi and gave the stock a “neutral” rating in a report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of €86.25 ($102.68).

Sanofi (SAN) opened at €71.13 ($84.68) on Tuesday. Sanofi has a 52-week low of €70.09 ($83.44) and a 52-week high of €92.97 ($110.68). The stock has a market cap of $89,850.00 and a PE ratio of 19.70.

WARNING: This piece of content was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://stocknewstimes.com/2018/01/23/barclays-reiterates-65-00-price-target-for-sanofi-san.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply